
Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Investment analysts at Brookline Capital Markets lifted their FY2026 EPS estimates for shares of Monopar Therapeutics in a report released on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver now forecasts that the company will post earnings per share of ($2.61) for the year, up from their previous estimate of ($2.70). The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($2.64) per share. Brookline Capital Markets also issued estimates for Monopar Therapeutics’ Q4 2026 earnings at ($0.80) EPS.
Several other research analysts also recently issued reports on MNPR. Morgan Stanley upped their price objective on Monopar Therapeutics from $130.00 to $133.00 and gave the stock an “overweight” rating in a report on Monday. Barclays reissued an “overweight” rating and issued a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. UBS Group set a $125.00 target price on Monopar Therapeutics in a research report on Thursday, July 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, October 15th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $123.12.
Monopar Therapeutics Price Performance
MNPR stock opened at $70.75 on Tuesday. The company has a 50 day moving average price of $79.98 and a 200 day moving average price of $77.50. Monopar Therapeutics has a fifty-two week low of $50.07 and a fifty-two week high of $124.82. The stock has a market capitalization of $479.47 million, a PE ratio of -29.36 and a beta of 1.62.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.72).
Institutional Trading of Monopar Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp lifted its stake in shares of Monopar Therapeutics by 24.1% in the 3rd quarter. State Street Corp now owns 229,771 shares of the company’s stock valued at $18,306,000 after purchasing an additional 44,669 shares during the period. Siren L.L.C. grew its stake in shares of Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after purchasing an additional 57,820 shares during the period. ADAR1 Capital Management LLC grew its stake in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares during the period. Bank of New York Mellon Corp acquired a new stake in shares of Monopar Therapeutics during the second quarter worth $7,124,000. Finally, Goldman Sachs Group Inc. increased its holdings in Monopar Therapeutics by 443.8% in the third quarter. Goldman Sachs Group Inc. now owns 87,877 shares of the company’s stock valued at $7,001,000 after purchasing an additional 71,716 shares during the last quarter. Institutional investors own 1.83% of the company’s stock.
Insider Buying and Selling at Monopar Therapeutics
In related news, Director Christopher M. Starr sold 8,400 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the transaction, the director directly owned 5,173 shares in the company, valued at $406,080.50. This represents a 61.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim R. Tsuchimoto sold 2,891 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $71.26, for a total transaction of $206,012.66. Following the completion of the transaction, the director directly owned 1,199 shares in the company, valued at approximately $85,440.74. The trade was a 70.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 51,920 shares of company stock worth $4,527,913 in the last 90 days. Corporate insiders own 9.70% of the company’s stock.
About Monopar Therapeutics
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.
Recommended Stories
- Five stocks we like better than Monopar Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
